Not finding it? Sign in to also search OpenAlex live.
-
Platelet-Instructed SPP1 Macrophages Drive Myofibroblast Activation in Fibrosis in a CXCL4-Dependent Manner2022 Journal of the American Society of Nephrology conference-abstract Medicine Cardiac Fibrosis and Remodeling Open access
Konrad Hoeft, Gideon J L Schaefer, David Schumacher, Hyoijn Kim, Barbara M. Klinkhammer, Christoph Kuppe, +3 more
0citations -
Pharmacological ACC inhibition decreases thrombin-induced platelet aggregation by a mechanism independent of lipid content2020 Archives of Cardiovascular Diseases Supplements conference-abstract Medicine Platelet Disorders and Treatments Open access
Marie Octave, Laurence Pirotton, Sophie Lepropre, Audrey Ginion, Valentine Robaux, Shakeel Kautbally, +7 more
0citations -
MO066: The Role of Platelet-Derived Growth Factor in Focal Segmental Glomerulosclerosis2022 Nephrology Dialysis Transplantation conference-abstract Medicine Renal Diseases and Glomerulopathies
Ting Jia, Tong Xu, Bart Smeets, Marcus Johannes Moeller, Jürgen Floege, Barbara M. Klinkhammer, +1 more
0citations -
Role of Platelet-Derived Growth Factor (PDGF) in Ex Vivo Aortic Calcification Under Uremic Conditions2022 Journal of the American Society of Nephrology conference-abstract Medicine Parathyroid Disorders and Treatments
Burcu Yesilyurt, Li Zhang, Barbara M. Klinkhammer, Julia Moellmann, Patrick Droste, Claudia Goettsch, +6 more
0citations -
PB1432 Small Interfering RNA-mediated Inhibition of Endothelial Von Willebrand Factor in Pro-Atherothrombotic Mice2023 Research and Practice in Thrombosis and Haemostasis conference-abstract Medicine Platelet Disorders and Treatments Open access
Yvonne K. Jongejan, Annika de Jong, Richard J. Dirven, Amanda C. M. Pronk, Sander Kooijman, Jeroen C.J. Eikenboom, +1 more
0citations -
A Phase 3, Randomized, Double-Blind, Active-Comparator-Controlled Study of Bomedemstat Versus Hydroxyurea in Patients with Essential Thrombocythemia Naïve to Cytoreductive Therapy2024 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, Jean‐Jacques Kiladjian, +14 more
2citations -
Shorespan-007: Phase 3 study of bomedemstat versus hydroxyurea in essential thrombocythemia naive to cytoreductive therapy.2025 Journal of Clinical Oncology conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Kristen Marie Pettit, Yuka Sugimoto, Eran Zimran, Yoshimitsu Shimomura, Hiroki Yamaguchi, Hans Carl Hasselbach, +14 more
0citations -
Identification of Paracrine Factors in the Early Cyst Microenvironment in Polycystic Kidney Disease2023 Journal of the American Society of Nephrology conference-abstract Biochemistry, Genetics and Molecular Biology Genetic and Kidney Cyst Diseases
Sevtap A. Yasinoglu, Thomas B. Kuipers, Hester Bange, Michael Eikmans, Hailiang Mei, Hans J. Baelde, +1 more
0citations -
Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis2023 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Naveen Pemmaraju, Adam J. Mead, Tim C. P. Somervaille, James K. McCloskey, Francesca Palandri, Steffen Koschmieder, +18 more
42citations -
Safety and Tolerability of AZD0466 As Monotherapy for Patients with Advanced Hematologic Malignancies. Results from a Phase I/II Trial2023 Blood conference-abstract Biochemistry, Genetics and Molecular Biology Cell death mechanisms and regulation
Shukaib Arslan, Giovanni Marconi, Giovanni Martinelli, Shaun A. Fleming, Antonio Curti, Shira Naomi Dinner, +19 more
5citations -
MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
2citations -
Fedratinib in combination with CC-486, an oral hypomethylating agent, in patients with accelerated phase myelofibrosis: Results from the phase I/II famy trial2025 Blood conference-abstract Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Nadja Jaekel, Susann Schulze, Christina Zahn, Andreas Wienke, Michael Richter, Steffen Koschmieder, +5 more
1citations -
A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)
John O Mascarenhas, Claire N. Harrison, Jean‐Jacques Kiladjian, Rami S. Komrokji, Steffen Koschmieder, Alessandro Maria Vannucchi, +9 more
1citations -
Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Neoplasms with Accompanying Paroxysmal Nocturnal Hemoglobinuria - a Study on Behalf of Cmwp and Saawp of the EBMT
Joanna Ewa Drozd-Sokolowska, Joe Tuffnell, Linda Köster, Uwe Platzbecker, Grzegorz Helbig, Pavel Jindra, +20 more
0citations